Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for serious diseases including oncology and obesity, has announced its participation in two major investor conferences this November.
The company will participate in a fireside chat at the UBS Global Healthcare Conference on November 13, 2024, at 8:45 a.m. PT at the Terranea Resort, Rancho Palos Verdes. Additionally, they will join the Jefferies London Healthcare Conference on November 19, 2024, at 5:00 p.m. GMT at the Waldorf Hilton, London.
Live webcasts of both presentations will be available on Terns' investor relations website and archived for at least 30 days.
Terns Pharmaceuticals (Nasdaq: TERN), un'azienda biofarmaceutica in fase clinica focalizzata nello sviluppo di trattamenti a piccole molecole per malattie gravi tra cui oncologia e obesità, ha annunciato la propria partecipazione a due importanti conferenze per investitori questo novembre.
L'azienda parteciperà a una chat informale alla UBS Global Healthcare Conference il 13 novembre 2024, alle 8:45 PT presso il Terranea Resort, Rancho Palos Verdes. Inoltre, parteciperanno alla Jefferies London Healthcare Conference il 19 novembre 2024, alle 17:00 GMT al Waldorf Hilton, Londra.
Le dirette streaming di entrambe le presentazioni saranno disponibili sul sito web delle relazioni con gli investitori di Terns e archiviate per almeno 30 giorni.
Terns Pharmaceuticals (Nasdaq: TERN), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de tratamientos con moléculas pequeñas para enfermedades graves como la oncología y la obesidad, ha anunciado su participación en dos importantes conferencias para inversores este noviembre.
La empresa participará en una charla informal en la UBS Global Healthcare Conference el 13 de noviembre de 2024 a las 8:45 a.m. PT en el Terranea Resort, Rancho Palos Verdes. Además, se unirán a la Jefferies London Healthcare Conference el 19 de noviembre de 2024 a las 5:00 p.m. GMT en el Waldorf Hilton, Londres.
Las transmisiones en vivo de ambas presentaciones estarán disponibles en el sitio web de relaciones con inversores de Terns y se archivarán durante al menos 30 días.
Terns Pharmaceuticals (Nasdaq: TERN)는 종양학 및 비만을 포함한 심각한 질병 치료를 위한 소분자 치료제 개발에 중점을 둔 임상 단계의 생명공학 회사로, 이번 11월 두 개의 주요 투자자 회의에 참여한다고 발표했습니다.
회사는 2024년 11월 13일 오전 8시 45분 PT에 Terranea Resort, Rancho Palos Verdes에서 열리는 UBS Global Healthcare Conference의 파이어사이드 채팅에 참석할 예정입니다. 또한, 2024년 11월 19일 오후 5시 GMT에 런던의 Waldorf Hilton에서 열리는 Jefferies London Healthcare Conference에도 참석할 것입니다.
두 프레젠테이션의 생중계는 Terns의 투자자 관계 웹사이트에서 제공되며 최소 30일 동안 아카이브됩니다.
Terns Pharmaceuticals (Nasdaq: TERN), une entreprise biopharmaceutique en phase clinique axée sur le développement de traitements à petites molécules pour des maladies graves telles que l'oncologie et l'obésité, a annoncé sa participation à deux grandes conférences d'investisseurs ce novembre.
L'entreprise participera à une discussion informelle lors de la UBS Global Healthcare Conference le 13 novembre 2024 à 8h45 PT au Terranea Resort, Rancho Palos Verdes. De plus, ils rejoindront la Jefferies London Healthcare Conference le 19 novembre 2024 à 17h00 GMT au Waldorf Hilton, Londres.
Des retransmissions en direct des deux présentations seront disponibles sur le site Web des relations avec les investisseurs de Terns et archivées pendant au moins 30 jours.
Terns Pharmaceuticals (Nasdaq: TERN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Kleinstmolekül-Behandlungen für schwerwiegende Krankheiten wie Onkologie und Fettleibigkeit konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im November bekannt gegeben.
Das Unternehmen wird am 13. November 2024 um 8:45 Uhr PT an einem Fire-Side-Chat auf der UBS Global Healthcare Conference im Terranea Resort, Rancho Palos Verdes, teilnehmen. Darüber hinaus werden sie am 19. November 2024 um 17:00 Uhr GMT auf der Jefferies London Healthcare Conference im Waldorf Hilton, London, teilnehmen.
Live-Streaming von beiden Präsentationen wird auf der Investor-Relations-Website von Terns verfügbar sein und mindestens 30 Tage lang archiviert werden.
- None.
- None.
FOSTER CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in November.
UBS Global Healthcare Conference
Format: Fireside Chat
Date and Time: Wednesday, November 13, 2024 at 8:45 a.m. PT
Location: Terranea Resort, Rancho Palos Verdes
Jefferies London Healthcare Conference
Format: Fireside Chat
Date and Time: Tuesday, November 19, 2024 at 5:00 p.m. GMT
Location: Waldorf Hilton, London
Live webcasts of the fireside chats will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com
FAQ
What investor conferences will Terns Pharmaceuticals (TERN) attend in November 2024?
When and where is Terns Pharmaceuticals (TERN) presenting at the UBS Global Healthcare Conference?
How can investors access Terns Pharmaceuticals (TERN) conference presentations?
